TSLA
Tesla
-- 355.840 NVDA
NVIDIA
-- 138.850 INTC
Intel
-- 23.600 NBIS
NEBIUS
-- 44.490 PLTR
Palantir
-- 119.160 
WEEKEND NEWS
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
Sutro Biopharma (NASDAQ: STRO) announced updated data from its Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for epithelial ovarian cancer (EOC) at ESMO 2024. Key findings include:
- 56% objective response rate at the recommended phase 2 dose (RP2D) of 4.3 mg/kg luvelta with 15 mg/kg bevacizumab
- 35% overall response rate across all dose ranges
- Efficacy observed regardless of Folate Receptor-α (FRα) expression
- No new safety signals compared to individual agents
- Expansion phase ongoing with 23 additional patients; data expected in H1 2025
The combination shows promise as a non-biomarker driven approach for EOC treatment, potentially benefiting a broader patient population.
- 56% objective response rate at the recommended phase 2 dose (RP2D) of 4.3 mg/kg luvelta with 15 mg/kg bevacizumab
- 35% overall response rate across all dose ranges
- Efficacy observed regardless of Folate Receptor-α (FRα) expression
- No new safety signals compared to individual agents
- Expansion phase ongoing with 23 additional patients; data expected in H1 2025
The combination shows promise as a non-biomarker driven approach for EOC treatment, potentially benefiting a broader patient population.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
8157
Followers
50
Following
93K
Visitors
Follow
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call